Summary

The Global ASEAN Point of Care Diagnostics Market is valued at approximately USD 1.03 billion in 2024 and is expected to register a promising compound annual growth rate (CAGR) of 4.70% over the forecast period from 2025 to 2035. Point of Care (PoC) Diagnostics has emerged as a pivotal enabler of decentralized healthcare delivery—empowering clinicians and patients alike with rapid diagnostic insights, often at the bedside or in near-patient settings. As ASEAN nations experience a surge in both urbanization and rural healthcare needs, PoC technologies are uniquely positioned to bridge gaps in access, responsiveness, and affordability. Whether addressing infectious diseases or chronic metabolic conditions, the real-time data rendered by these tools is reshaping clinical pathways and policy direction across Southeast Asia.
What’s fueling this momentum is the increasing burden of both communicable and non-communicable diseases, along with a parallel surge in awareness regarding early diagnosis and preventive care. The ASEAN region is witnessing a sharp rise in the demand for accessible, compact, and user-friendly diagnostic devices that can function even in low-resource environments. This, combined with advancements in molecular diagnostics and the integration of digital health infrastructure, is enabling a new generation of smart, portable PoC devices. Governments across ASEAN are also recognizing the utility of these solutions in pandemic preparedness, primary care reinforcement, and health equity expansion—creating fertile ground for innovation and investment.
From a regional perspective, Southeast Asia is undergoing a healthcare transformation. Countries like Singapore and Malaysia are investing heavily in precision diagnostics and digital health ecosystems, while Indonesia, Vietnam, and the Philippines are scaling their rural and public health infrastructures. These nations are leveraging PoC diagnostics to offset the limitations of centralized laboratory systems—particularly in remote or underserved regions. Meanwhile, Thailand’s thriving medical tourism and diagnostic manufacturing sectors have further enhanced regional production and cross-border technology transfers. The ASEAN bloc’s regulatory harmonization efforts and incentives for healthcare technology startups are also expected to accelerate cross-market adoption during the forecast period.
Major market player included in this report are:
• Abbott Laboratories
• Siemens Healthineers
• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific Inc.
• bioMérieux SA
• Becton, Dickinson and Company
• Danaher Corporation
• QuidelOrtho Corporation
• EKF Diagnostics Holdings plc
• Nova Biomedical Corporation
• Instrumentation Laboratory (Werfen)
• Trinity Biotech
• Sekisui Diagnostics LLC
• PTS Diagnostics
• Bio-Rad Laboratories, Inc.
Global ASEAN Point of Care Diagnostics Market Report Scope:
• Historical Data – 2023, 2024
• Base Year for Estimation – 2024
• Forecast period – 2025-2035
• Report Coverage – Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Regional Scope – North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope – Free report customization (equivalent up to 8 analysts’ working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segments of the market are explained below:
By Product:
• Infectious Disease
• TB
• Hepatitis
• STDs
• HAIs
• Glucose
• Cardiometabolic
• Pregnancy
• Coagulation
By Technology:
• Lateral Flow Assays
• Biochemistry
• Molecular Diagnostics (MDx)
By End User:
• Home Care
• Hospitals
By Region:
North America
• U.S.
• Canada
Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe
Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific
Latin America
• Brazil
• Mexico
Middle East & Africa
• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa
Key Takeaways:
• Market Estimates & Forecast for 10 years from 2025 to 2035.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

ページTOPに戻る

Table of Contents

Table of Contents
Chapter 1. Global ASEAN Point of Care Diagnostics Market Report Scope & Methodology
1.1. Research Objective
1.2. Research Methodology
1.2.1. Forecast Model
1.2.2. Desk Research
1.2.3. Top Down and Bottom-Up Approach
1.3. Research Attributes
1.4. Scope of the Study
1.4.1. Market Definition
1.4.2. Market Segmentation
1.5. Research Assumption
1.5.1. Inclusion & Exclusion
1.5.2. Limitations
1.5.3. Years Considered for the Study
Chapter 2. Executive Summary
2.1. CEO/CXO Standpoint
2.2. Strategic Insights
2.3. ESG Analysis
2.4. Key Findings
Chapter 3. Global ASEAN Point of Care Diagnostics Market Forces Analysis
3.1. Market Forces Shaping The Global ASEAN Point of Care Diagnostics Market (2024-2035)
3.2. Drivers
3.2.1. Rising burden of communicable and non-communicable diseases
3.2.2. Growing awareness regarding early diagnosis and preventive care
3.2.3. Government initiatives and investments in primary healthcare
3.3. Restraints
3.3.1. Regulatory complexities across ASEAN countries
3.3.2. Limited infrastructure in remote regions
3.4. Opportunities
3.4.1. Integration of digital health with PoC diagnostics
3.4.2. Rising investment in healthcare innovation across Southeast Asia
Chapter 4. Global ASEAN Point of Care Diagnostics Industry Analysis
4.1. Porter’s 5 Forces Model
4.1.1. Bargaining Power of Buyer
4.1.2. Bargaining Power of Supplier
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Porter’s 5 Force Forecast Model (2024-2035)
4.3. PESTEL Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.3.5. Environmental
4.3.6. Legal
4.4. Top Investment Opportunities
4.5. Top Winning Strategies (2025)
4.6. Market Share Analysis (2024-2025)
4.7. Global Pricing Analysis And Trends 2025
4.8. Analyst Recommendation & Conclusion
Chapter 5. Global ASEAN Point of Care Diagnostics Market Size & Forecasts by Product 2025-2035
5.1. Infectious Disease
5.1.1. TB
5.1.2. Hepatitis
5.1.3. STDs
5.1.4. HAIs
5.2. Glucose
5.3. Cardiometabolic
5.4. Pregnancy
5.5. Coagulation
Chapter 6. Global ASEAN Point of Care Diagnostics Market Size & Forecasts by Technology 2025–2035
6.1. Lateral Flow Assays
6.2. Biochemistry
6.3. Molecular Diagnostics (MDx)
Chapter 7. Global ASEAN Point of Care Diagnostics Market Size & Forecasts by End User 2025–2035
7.1. Home Care
7.2. Hospitals
Chapter 8. Global ASEAN Point of Care Diagnostics Market Size & Forecasts by Region 2025–2035
8.1. North America
8.1.1. U.S.
8.1.2. Canada
8.2. Europe
8.2.1. UK
8.2.2. Germany
8.2.3. France
8.2.4. Spain
8.2.5. Italy
8.2.6. Rest of Europe
8.3. Asia Pacific
8.3.1. China
8.3.2. India
8.3.3. Japan
8.3.4. Australia
8.3.5. South Korea
8.3.6. Rest of Asia Pacific
8.4. Latin America
8.4.1. Brazil
8.4.2. Mexico
8.5. Middle East & Africa
8.5.1. UAE
8.5.2. Saudi Arabia
8.5.3. South Africa
8.5.4. Rest of Middle East & Africa
Chapter 9. Competitive Intelligence
9.1. Top Market Strategies
9.2. Abbott Laboratories
9.2.1. Company Overview
9.2.2. Key Executives
9.2.3. Company Snapshot
9.2.4. Financial Performance (Subject to Data Availability)
9.2.5. Product/Services Port
9.2.6. Recent Development
9.2.7. Market Strategies
9.2.8. SWOT Analysis
9.3. Siemens Healthineers
9.4. F. Hoffmann-La Roche Ltd
9.5. Thermo Fisher Scientific Inc.
9.6. bioMérieux SA
9.7. Becton, Dickinson and Company
9.8. Danaher Corporation
9.9. QuidelOrtho Corporation
9.10. EKF Diagnostics Holdings plc
9.11. Nova Biomedical Corporation
9.12. Instrumentation Laboratory (Werfen)
9.13. Trinity Biotech
9.14. Sekisui Diagnostics LLC
9.15. PTS Diagnostics
9.16. Bio-Rad Laboratories, Inc.